{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=31", "query": { "condition": "Skin and Connective Tissue Disease", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 15608, "total_pages": 1561, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T00:20:02.179Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03585296", "title": "A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "ATI-502", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aclaris Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-07-10", "completion_date": "2019-04-25", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 6, "location_summary": "Encinitas, California • San Diego, California • Fridley, Minnesota + 3 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "Bexley", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585296" }, { "nct_id": "NCT00001596", "title": "Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Albinism", "Inborn Errors of Metabolism", "Oculocutaneous Albinism", "Platelet Storage Pool Deficiency", "Pulmonary Fibrosis" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William Gahl, M.D.", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-09", "completion_date": "2016-05-09", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001596" }, { "nct_id": "NCT05932862", "title": "A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "XL309", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 429, "start_date": "2024-04-03", "completion_date": "2029-08-03", "has_results": false, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 16, "location_summary": "Fountain Valley, California • Jacksonville, Florida • Orlando, Florida + 12 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05932862" }, { "nct_id": "NCT06972446", "title": "A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lutikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ravagalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-06-20", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 49, "location_summary": "Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06972446" }, { "nct_id": "NCT04413942", "title": "Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "FB825", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Oneness Biotech Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 99, "start_date": "2020-03-10", "completion_date": "2022-06-30", "has_results": false, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 18, "location_summary": "Beverly Hills, California • Encino, California • Huntington Beach, California + 13 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04413942" }, { "nct_id": "NCT00898573", "title": "Lapatinib Resistance in Patients With Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "cell sorting", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2008-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-02", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 9, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898573" }, { "nct_id": "NCT04697069", "title": "A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acneiform Eruptions" ], "interventions": [ { "name": "Imsidolimab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanda Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2021-05-04", "completion_date": "2021-12-13", "has_results": true, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697069" }, { "nct_id": "NCT02915666", "title": "A Clinical Trial of Patients With Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Digoxin Combination", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-10", "completion_date": "2017-07-17", "has_results": false, "last_update_posted_date": "2018-05-15", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915666" }, { "nct_id": "NCT02713022", "title": "Body Composition and White Adipose Tissue Inflammation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Prostate Cancer", "Body Composition", "White Adipose Tissue Inflammation" ], "interventions": [ { "name": "DEXA Scan", "type": "DEVICE" }, { "name": "Godin Leisure Time Exercise Questionnaire (GLTEQ)", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2015-11-04", "completion_date": "2023-11-07", "has_results": false, "last_update_posted_date": "2023-11-08", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 9, "location_summary": "Milford, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Milford", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713022" }, { "nct_id": "NCT01400451", "title": "Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab (BMS-734016)", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-01-01", "last_synced_at": "2026-10-31T00:20:02.179Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400451" } ] }